Alzheimer’s disease and other dementias
Dementia describes a collection of symptoms that are caused by disorders affecting the brain. Alzheimer’s disease is the most common form of dementia. If someone has Alzheimer’s, they may have problems with memory, thinking skills, emotions, behaviour and mood. As the disease progresses, brain function is affected enough to interfere with the person’s normal social or working life.
Alzheimer’s occurs when abnormal protein builds up inside and outside the brain. The cells in the brain eventually die, damaging the connections between the brain’s cells. The loss of these connections lead to the loss of brain function as symptoms of the disease develop. As Alzheimer’s disease moves through each area of the brain, certain functions or abilities are lost.
How The Florey is making a difference
The Florey is a world leader in Alzheimer’s research, having discovered the major pathology of the disease and, by using biomarkers, defined the natural history of Alzheimer’s disease over its decade-long development prior to symptoms.
Research at the Florey extends from fundamental research in the laboratory through to developing biomarkers and performing clinical trials for Alzheimer’s treatment.
Florey scientists are hard at work discovering new drug targets and developing drugs, and we have a history of taking promising new drugs all the way to clinical trial.
Florey scientists are also discovering new biomarkers for dementia, and are currently implementing validated biomarkers in memory services in Australia.
Researcher spotlight
Dr Pratishtha Chatterjee’s research encompasses the investigation of diagnostic, prognostic and longitudinal monitoring biomarkers for Alzheimer’s disease and other dementia.
Through her research, she aims to improve patient management strategies in clinical practice, as well as improve design of clinical trials facilitating the development of disease modifying therapies.
Research projects
- Biological inorganic chemistry of copper in the early ubiquitination pathways
- Biomarker discovery for neurodegenerative disease
- Blood testing to predict and discriminate dementias
- Can we achieve precise medication use in people living with Alzheimer’s disease?
- Can we identify novel biomarkers for early detection of Alzheimer’s disease?
Research groups
- Antibody Therapeutics Group
- Epigenetics and Neural Plasticity Group
- Extracellular Vesicle Group
- Genes, Environment and Behaviour Group
- Molecular Gerontology Group
- Neurodegeneration and Neuropathology Group
- Neuroinflammation Group
- Neurotherapeutics Group
- Oxidation Biology Group
- Peptide and Oligonucleotide Therapeutics Group
More information
For support or further information, contact Dementia Australia or Dementia Support Australia. While The Florey researches dementia and Alzheimer’s disease we do not offer medical advice or treatment.
Latest news
Latest Florey news on Alzheimer’s disease and other dementias